Manifesto on inhaled triple therapy in asthma: an Interasma (Global Asthma Association - GAA) document

Article Allergy

Manifesto on united airways diseases (UAD): an Interasma (global asthma association - GAA) document

Angelica Tiotiu et al.

Summary: This article addresses the issue of upper and lower airways diseases, advocating for challenging assumptions, fostering commitment, and bringing about change. It emphasizes the impact of UAD on patient health status and medical needs.

JOURNAL OF ASTHMA (2022)

添加到收藏夹

Article Geriatrics & Gerontology

Bridging the divide between biomedical and psychosocial approaches in dementia research: the 2019 INTERDEM manifesto

Myrra Vernooij-Dassen et al.

Summary: The article aims to provide a new perspective on integrated biomedical and psychosocial dementia research, highlighting the importance of social health in promoting cognitive reserve in dementia patients. By bridging biomedical and psychosocial paradigms, the Manifesto presented in the article offers guidance on significantly advancing the dementia research agenda.

AGING & MENTAL HEALTH (2021)

添加到收藏夹

Article Allergy

Safety of Once-Daily Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol in Japanese Patients with Asthma: A Long-Term (52-Week) Phase III Open-Label Study

Soichiro Hozawa et al.

Summary: This study evaluated the long-term safety of FF/UMEC/VI in Japanese patients with asthma for 52 weeks and found that the treatment was well-tolerated without any new safety concerns.

JOURNAL OF ASTHMA AND ALLERGY (2021)

添加到收藏夹

Article Critical Care Medicine

Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial

Laurie A. Lee et al.

Summary: In patients with uncontrolled moderate or severe asthma using ICS/LABA, adding UMEC improved lung function but did not significantly reduce moderate and/or severe exacerbations. Single-inhaler FF/UMEC/VI is an effective treatment option with a favorable risk-benefit profile. Higher dose FF primarily reduced exacerbations, especially in patients with elevated biomarkers of type 2 airway inflammation. Further studies are needed to confirm the effects of type 2 inflammatory biomarkers on treatment outcomes in asthma.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Allergy

Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses

Alberto Papi et al.

Summary: This study showed that there is a marked seasonal effect on asthma exacerbations, with the rate highest in winter months for patients who received BDP/FF alone. However, the addition of the long-acting muscarinic antagonist component to BDP/FF reduced this seasonal variation, especially during winter, resulting in a significant reduction in the relative effect of BDP/FF/G versus BDP/FF.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Article Allergy

Cost-Effectiveness of Tiotropium in Elderly Patients with Severe Asthma Using Real-World Data

Sung-Hyun Hong et al.

Summary: The study evaluated the cost-effectiveness of adding tiotropium to inhaled corticosteroids and long-acting beta-agonists in elderly patients with severe asthma using real-world data. Results showed that tiotropium was cost-effective in patients with poorly controlled symptoms, while it was not a cost-effective alternative overall. The study provided important real-world evidence for establishing reimbursement criteria for tiotropium in elderly patients with severe asthma.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

添加到收藏夹

Article Oncology

Why is appropriate healthcare inaccessible for many European breast cancer patients? - The EBCC 12 manifesto

Fatima Cardoso et al.

Summary: In Europe, inappropriate reimbursement policies hinder optimal breast cancer care and were discussed in the 12th European Breast Cancer Conference. Patient involvement is crucial in driving changes to clinical practice. While reimbursement policies may differ among European countries, similar issues exist and broad solutions can be applied to improve care.

BREAST (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN)

Shuying Yang et al.

Summary: This study characterized the pharmacokinetics of inhaled corticosteroid (FF), long-acting muscarinic antagonist (UMEC), and long-acting beta(2)-agonist (VI) when administered as dual or triple single-inhaler therapy in asthma patients. Marginal covariate effects were observed, but no dose adjustments are necessary for FF, UMEC, or VI. Systemic exposure of FF or VI did not differ between triple or dual therapy and was similar to patients with chronic obstructive pulmonary disease.

CLINICAL PHARMACOKINETICS (2021)

添加到收藏夹

Review Medicine, General & Internal

Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma A Systematic Review and Meta-analysis

Lisa H. Y. Kim et al.

Summary: The systematic synthesis of outcomes from 20 randomized clinical trials revealed that triple therapy (ICS, LABA, and LAMA) was significantly associated with reduced risk of severe asthma exacerbations and modest improvements in asthma control compared to dual therapy (ICS plus LABA), with no significant differences in quality of life or mortality.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials

Emil Scosyrev et al.

Summary: The study evaluated the cardiovascular safety of two new inhaled fixed-dose combinations for asthma treatment, finding that the frequency of cardiovascular events was low with no notable differences between comparison groups.

RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Allergy

Real-life management of patients with severe asthma in the biologics era: Can we do better?

Jeremy Charriot et al.

Summary: This study investigated the treatment profile of severe asthma patients in France in 2018, revealing discrepancies between guidelines and real-life practice. The findings emphasized the need for improved patient phenotyping and provided insight into the positioning of current and forthcoming biologics.

WORLD ALLERGY ORGANIZATION JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study

Yoichi Nakamura et al.

Summary: In the CAPTAIN study, FF/UMEC/VI improved lung function, symptoms, and asthma control compared to FF/VI in patients with inadequately controlled asthma. The efficacy and safety of FF/UMEC/VI in the Japanese cohort were consistent with the overall study population.

CURRENT MEDICAL RESEARCH AND OPINION (2021)

添加到收藏夹

Article Respiratory System

Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial

Jutta Beier et al.

Summary: Once-daily inhaled IND/GLY/MF showed significant improvement in lung function and safety profile in patients with mild-moderate asthma, regardless of morning or evening dosing. The treatment demonstrated increased FEV1 and PEF over 14 days, with a safety profile comparable to placebo.

ERJ OPEN RESEARCH (2021)

添加到收藏夹

Article Respiratory System

Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population

Hironori Sagara et al.

Summary: The IRIDIUM study demonstrated the efficacy of IND/GLY/MF versus IND/MF and SAL/FLU in Asian patients with inadequately controlled asthma. IND/GLY/MF showed greater improvements in lung function, reduced asthma exacerbations, and provided comparable asthma control over 52 weeks.

BMJ OPEN RESPIRATORY RESEARCH (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Efficacy of once-daily tiotropium Respimat in adults with asthma at GINA Steps 2-5

Roland Buhl et al.

PULMONARY PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹

Article Medicine, General & Internal

Clinical characteristics, treatment patterns, disease burden, and persistence/adherence in patients with asthma initiating inhaled triple therapy: real-world evidence from Japan

Takeo Suzuki et al.

CURRENT MEDICAL RESEARCH AND OPINION (2020)

添加到收藏夹

Letter Respiratory System

Extrafine triple therapy in patients with asthma and persistent airflow limitation

Dave Singh et al.

EUROPEAN RESPIRATORY JOURNAL (2020)

添加到收藏夹

Article Respiratory System

Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Improves Inspiratory Capacity in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap

Yoshihisa Ishiura et al.

INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)

Christian Gessner et al.

RESPIRATORY MEDICINE (2020)

添加到收藏夹

Article Allergy

Tiotropium Respimat Efficacy and Safety in Asthma: Relationship to Age

Dennis E. Doherty et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)

添加到收藏夹

Article Critical Care Medicine

Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study

Huib A M Kerstjens et al.

Lancet Respiratory Medicine (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

A manifesto of collaborative longitudinal cardiovascular care in heart failure

Anuradha Lala et al.

HEART FAILURE REVIEWS (2020)

添加到收藏夹

Article Allergy

Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry

Francesca Puggioni et al.

JOURNAL OF ASTHMA AND ALLERGY (2020)

添加到收藏夹

Article Respiratory System

Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER

Dave Singh et al.

RESPIRATORY RESEARCH (2020)

添加到收藏夹

Letter Respiratory System

Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study

Henrik Watz et al.

RESPIRATORY RESEARCH (2020)

添加到收藏夹

Article Allergy

Comparison between montelukast and tiotropium as add-on therapy to inhaled corticosteroids plus a long-acting β2-agonist in for patients with asthma

Makoto Hoshino et al.

JOURNAL OF ASTHMA (2019)

添加到收藏夹

Letter Allergy

Tiotropium reduces airflow obstruction in asthma patients, independent of body mass index

Sandhya Khurana et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2019)

添加到收藏夹

Article Medicine, General & Internal

Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials

Johann Christian Virchow et al.

LANCET (2019)

添加到收藏夹

Article Allergy

Characterizing Real-World Use Of Tiotropium In Asthma In The USA

Carlyne M. Averell et al.

JOURNAL OF ASTHMA AND ALLERGY (2019)

添加到收藏夹

Review Medicine, General & Internal

Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma A Systematic Review and Meta-analysis

Diana M. Sobieraj et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

添加到收藏夹

Article Medicine, Research & Experimental

Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma

Li Zhang et al.

MEDICAL SCIENCE MONITOR (2018)

添加到收藏夹

Article Allergy

Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype

Thomas B. Casale et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2018)

添加到收藏夹

Article Health Care Sciences & Services

Repurposing Medications for Hospice/Palliative Care Symptom Control Is No Longer Sufficient: A Manifesto for Change

David C. Currow et al.

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Effects of tiotropium on lung function in current smokers and never smokers with bronchial asthma

Makoto Yoshida et al.

PULMONARY PHARMACOLOGY & THERAPEUTICS (2017)

添加到收藏夹

Article Allergy

Effects of the addition of tiotropium on airway dimensions in symptomatic asthma

Makoto Hoshino et al.

ALLERGY AND ASTHMA PROCEEDINGS (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status

Huib A. M. Kerstjens et al.

RESPIRATORY MEDICINE (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Once-daily tiotropium Respimat (R) 5 mu g is an efficacious 24-h bronchodilator in adults with symptomatic asthma

Wolfgang Timmer et al.

RESPIRATORY MEDICINE (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study

Ken Ohta et al.

PLOS ONE (2015)

添加到收藏夹

Article Pharmacology & Pharmacy

Effects of tiotropium on lung function in severe asthmatics with or without emphysematous changes

Makoto Yoshida et al.

PULMONARY PHARMACOLOGY & THERAPEUTICS (2013)

添加到收藏夹

Article Medicine, General & Internal

Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy

Huib A. M. Kerstjens et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Allergy

Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial

Huib A. M. Kerstjens et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Improvements with tiotropium in COPD patients with concomitant asthma

H. Magnussen et al.

RESPIRATORY MEDICINE (2008)

添加到收藏夹

Manifesto on inhaled triple therapy in asthma: an Interasma (Global Asthma Association - GAA) document

相关参考文献

导出引文

分享论文